Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
98.93
-1.95 (-1.93%)
May 21, 2026, 11:31 AM EDT - Market open
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Protagonist Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $117.33. The average 1-year stock price forecast is 18.60% higher than the current stock price, while the lowest is $100 (+1.08%) and the highest is $137 (+38.48%).
Price Target: $117.33 (+18.60%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Protagonist Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 6 | 6 | 7 | 7 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 11 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $120 → $137 | Buy | Maintains | $120 → $137 | +38.48% | May 6, 2026 |
| Wedbush | Wedbush | Buy Maintains $112 → $118 | Buy | Maintains | $112 → $118 | +19.28% | May 6, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $110 → $121 | Strong Buy | Maintains | $110 → $121 | +22.31% | Apr 15, 2026 |
| Clear Street | Clear Street | Strong Buy Maintains $104 → $116 | Strong Buy | Maintains | $104 → $116 | +17.25% | Apr 7, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $107 → $110 | Buy | Maintains | $107 → $110 | +11.19% | Mar 19, 2026 |
Financial Forecast
Revenue This Year
510.92M
from 46.02M
Increased by 1,010.31%
Revenue Next Year
135.95M
from 510.92M
Decreased by -73.39%
EPS This Year
3.98
from -2.05
EPS Next Year
-1.12
from 3.98
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 602.7M | 230.8M | ||||||
| Avg | 510.9M | 136.0M | ||||||
| Low | 126.4M | 52.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1,209.8% | -54.8% | ||||||
| Avg | 1,010.3% | -73.4% | ||||||
| Low | 174.7% | -89.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 5.92 | 2.11 | ||||||
| Avg | 3.98 | -1.12 | ||||||
| Low | -0.98 | -2.70 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | -47.0% | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.